Moderna, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Moderna, Inc. (MRNA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 6.71 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-02-20
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2021-12-31 was 200.00K shares, a 27.93% increase year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2021-09-30 was 410.00K shares, a 63.51% decline year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2021-06-30 was 360.00K shares, a 10.65% decline year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2021-03-31 was 90.00K shares, a 90.47% decline year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 6.71M shares, a 515.60% increase from fiscal 2024.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 1.09M shares, a 60.29% increase from fiscal 2023.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 680.00K shares, a 74.36% increase from fiscal 2022.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 390.00K shares, a 63.21% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 6.71M shares 10-K · filed 2026-02-20 | |||
| 2024-12-31 | 1.09M shares 10-K · filed 2025-02-21 | |||
| 2023-12-31 | 680.00K shares 10-K · filed 2024-02-23 | |||
| 2022-12-31 | 390.00K shares 10-K · filed 2023-02-24 | |||
| 2021-12-31 | 200.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | 610.00K shares derived: sum of 2 quarters · filed 2022-02-25 | 970.00K shares derived: sum of 3 quarters · filed 2022-02-25 | 1.06M shares 10-K · filed 2022-02-25 |
| 2021-09-30 | 410.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 770.00K shares derived: sum of 2 quarters · filed 2021-11-04 | 860.00K shares 10-Q · filed 2021-11-04 | 1.02M shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 360.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 450.00K shares 10-Q · filed 2021-08-05 | 606.34K shares derived: sum of 3 quarters · filed 2021-08-05 | 1.73M shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 90.00K shares 10-Q · filed 2021-05-06 | 246.34K shares derived: sum of 2 quarters · filed 2021-05-06 | 1.37M shares derived: sum of 3 quarters · filed 2021-05-06 | 1.77M shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 156.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | 1.28M shares derived: sum of 2 quarters · filed 2021-02-26 | 1.68M shares derived: sum of 3 quarters · filed 2021-02-26 | 2.63M shares 10-K · filed 2021-02-26 |
| 2020-09-30 | 1.12M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | 1.53M shares derived: sum of 2 quarters · filed 2020-10-30 | 2.47M shares 10-Q · filed 2020-10-30 | 3.32M shares derived: sum of 4 quarters · filed 2020-10-30 |
| 2020-06-30 | 402.93K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 1.35M shares 10-Q · filed 2020-08-06 | 2.19M shares derived: sum of 3 quarters · filed 2020-08-06 | 2.97M shares derived: sum of 4 quarters · filed 2020-08-06 |
| 2020-03-31 | 944.72K shares 10-Q · filed 2020-05-07 | 1.79M shares derived: sum of 2 quarters · filed 2020-05-07 | 2.57M shares derived: sum of 3 quarters · filed 2020-05-07 | 3.65M shares derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | 846.26K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | 1.63M shares derived: sum of 2 quarters · filed 2020-02-27 | 2.71M shares derived: sum of 3 quarters · filed 2020-02-27 | 5.69M shares 10-K · filed 2020-02-27 |
| 2019-09-30 | 779.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | 1.86M shares derived: sum of 2 quarters · filed 2019-11-06 | 4.85M shares 10-Q · filed 2019-11-06 | |
| 2019-06-30 | 1.08M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | 4.07M shares 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | 2.99M shares 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | 1.64M shares 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |